NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/03/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,993.22 mln
Float62.12 mln
Earnings Date11/10/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
29.46
Highly suspicious
1-Year Forecast
46.46
Exceptional upside
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.01
Debt-free
Pre-Tax Margin
-758%
Severely loss-making
Business Description
Stoke Therapeutics is a biotechnology company focused on treating serious genetic diseases by using a proprietary technology to boost the production of proteins that patients cannot make in sufficient quantities. Its two leading drug candidates target Dravet syndrome, a severe form of epilepsy, and autosomal dominant optic atrophy, a condition that causes progressive vision loss, with the Dravet syndrome treatment currently in late-stage clinical trials. The company works alongside Biogen and Acadia Pharmaceuticals to develop and bring these medicines to patients. Founded in 2014 and based in Bedford, Massachusetts, Stoke is also exploring treatments for other diseases where a single faulty gene disrupts normal function in the brain and eye.
